ArticleGut2024
Protective function of sclerosing cholangitis on IBD.
Article in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Triptolide loaded cerium oxide nanozyme based oral nanoplatform for targeted colitis therapy.International journal of pharmaceutics: X · 2026Article
- Article
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- Integrin α4β7: Pathogenic Roles in Metabolic and Inflammatory Diseases and Translational Therapeutics.Journal of inflammation research · 2026Review
- Thalidomide-mediated immunomodulation in a patient withFrontiers in immunology · 2026Article
- A case of pregnancy complicated by caroli disease.BMC pregnancy and childbirth · 2025Article
- Long-Term Clinical and Endoscopic Outcomes of Crohn's Disease Following Liver Transplantation: A Multicenter Cohort Study.Biomedicines · 2025Article
- Unraveling the Converging Roles of ASC-Dependent Inflammasomes, Interleukin-1 Superfamily Members, Serum Amyloid A, and Non-Sterile Inflammation in Disease Pathology and Fibrosis in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Risk factors for recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients: A meta-analysis.World journal of gastrointestinal surgery · 2025Article
- Elevated long-to-very-long-chain ceramide ratio correlates with disease severity in inflammatory bowel disease and primary sclerosing cholangitis.Scientific reports · 2025Article
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Article
- Influence of biological sex in inflammatory bowel diseases.Nature reviews. Gastroenterology & hepatology · 2025Review
- 2'-Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota and Buffers Experimental Colitis in Mice: An Integrating Investigation of Colonic Proteomics and Gut Microbiota Analysis.Food science & nutrition · 2025Article
- Endoplasmic reticulum stress in gut inflammation: Implications for ulcerative colitis and Crohn's disease.World journal of gastroenterology · 2025Review
- Comparable Long-Term Liver Transplant Outcomes in Primary Sclerosing Cholangitis with and without MASLD: Last Decade Analysis of the UNOS Database.Digestive diseases (Basel, Switzerland) · 2025Article
- Bile acids as therapeutic agents.Frontiers in pharmacology · 2025Review
- Seeing the whole picture: Inflammatory bowel disease complications and extraintestinal manifestations on cross-sectional imaging.United European gastroenterology journal · 2024Article
- Colitis Ameliorates Murine Autoimmune Cholangitis Through Polarization of M2 Macrophages and Inhibition of CD8In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is a strong clinical association between IBD and primary sclerosing cholangitis (PSC), a chronic disease of the liver characterised by biliary inflammation that leads to strictures and fibrosis. Approximately 60%-80% of people with PSC will also develop IBD (PSC-IBD). One hypothesis explaining this association would be that PSC drives IBD. Therefore, our aim was to test this hypothesis and to decipher the underlying mechanism.
designColitis severity was analysed in experimental mouse models of colitis and sclerosing cholangitis, and people with IBD and PSC-IBD. Foxp3
resultsWe show that sclerosing cholangitis attenuated IBD in mouse models. Mechanistically, sclerosing cholangitis causes an altered intestinal microbiota composition, which promotes Foxp3
conclusionThis study shows that PSC attenuates IBD and provides a comprehensive insight into the mechanisms involved in this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.